康臣葯業(01681.HK)與倍特藥業訂立戰略合作協議
康臣葯業(01681.HK)公布,與成都倍特藥業就造影劑領域的戰略合作訂立一項戰略合作協議。據此,雙方希望在造影劑系列產品的原料藥和製劑研發申報、及市場開發方面進行合作。在生產階段,公司將負責生產造影劑製劑,倍特藥業將成為造影劑原料藥的首選供應商。
同時,訂立一項有關某型碘劑項目三方合作協議,主要內容為由倍特藥業開展某型碘造影劑製劑的研發工作,並協助公司完成該型碘造影劑製劑相關的申報和註冊等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.